Jasper Therapeutics(JSPR) - 2025 Q4 - Annual Results

Financial Performance - Jasper reported a net loss of $9.1 million for Q4 2025, with a basic and diluted net loss per share of $0.32[6] - Total operating expenses for the year ended December 31, 2025, were $83.9 million, compared to $76.2 million in 2024[10] - The company's accumulated deficit as of December 31, 2025, was $316.7 million, up from $240.9 million in the previous year[12] Research and Development - Research and development expenses for Q4 2025 totaled $11.4 million, while general and administrative expenses were $4.5 million[6] - The company plans to commence patient enrollment for the Phase 2b study in chronic spontaneous urticaria (CSU) in the second half of 2026, pending capital availability[2] - Jasper completed an internal investigation into the lack of clinical response in previous BEACON data, confirming no issues with the drug product used[3] Clinical Study Results - In the BEACON study, 67% of patients in Cohort 9.1 achieved a complete response at 12 weeks, with a mean UAS7 reduction of 31 points[3] - 75% of participants in the open-label extension study achieved a complete response or well-controlled disease at 12 weeks[3] - Positive preliminary data from the ETESIAN study indicated reductions in airway hyperresponsiveness after a single 180mg dose of briquilimab[6] Cash Position - Cash and cash equivalents as of December 31, 2025, amounted to $28.7 million, a decrease from $71.6 million in the previous year[6]